Blocking the CCR5 receptor on neurons enhanced the recovery from stroke and traumatic brain injury in animal studies, and patients with the delta32 mutation in CCR5, which renders the receptor nonfunctional, showed better recovery after mild to moderate stroke in the TABASCO clinical trial.